Condition
Liver Disease
Locations
China
Start date
03/06/2026
Identifiers
Trial ID DAS-8853,
NCT number NCT07682363,
Eudract number Not Available
NCT number NCT07682363,
Eudract number Not Available
Summary
This study is a cross-sectional survey-based study. The main goal of this study is to investigate the attitudes, perceptions, and clinical practice in assessing liver fibrosis following a metabolic dysfunction-associated steatotic liver disease (MASLD) diagnosis, and the management of MASLD patients among Chinese physicians in the departments of endocrinology / hepatology / infection / gastroenterology in Grade IIIA hospitals in provincial capitals or municipalities.
Trial Overview:
Treatment
OTHER: No treatment is given
Study type
OBSERVATIONAL
Trial duration
Jun 03 2026 - Feb 23 2027
Participants
470
Phase
Not Available
Are you eligible?
Gender
Male and female
Age
18 years and older
Find out how you can participate
Questions or concerns
Do you have any question about what it’s like being a clinical volunteer? Have a look at our answers to frequently asked questions.
This site contains information about clinical trials sponsored by Novo Nordisk. It is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. The information on this site should not be relied on as the basis for any decision or action. Only a physician can determine whether a specific product is correct for a particular patient. If you have questions regarding any information contained on this site you should consult a physician.